3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

Adverse pregnancy outcomes in HIV infected women treated with HAART in Abidjan Côte d'Ivoire

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. TuFo0202

Tonwe-Gold B., Becquet R., Kone M., Ayekoe I., Viho I., Toure P., Ekouevi D.K., Abrams E.J., Dabis F., Leroy V.
1Programme MTCT-Plus, ACONDA, Abidjan, Côte d'Ivoire, 2Unité INSERM 593, Institut de Santé Publique, Epidémiologie et Développement (ISPED), Bordeaux, France, 3The MTCT-Plus Initiative, Mailman School of Public Healths, Columbia University, New-York, United States of America

INTRODUCTION: Pregnancy outcomes for women on HAART in low resource settings have not been well described. Our purpose was to investigate this issue within the MTCT-Plus Initiative in Abidjan, Cote d'Ivoire, a care and treatment program for HIV-infected women and their families.

METHODS: HIV-infected pregnant women who met eligibility criteria (WHO stage 4, stage 2 or 3 with CD4 count <350mm³ and CD4 <200mm³ [HAART group]) were treated with HAART (ZDV+3TC+NVP). The women not eligible for HAART received standard PMTCT prophylaxis(ZDV+3TC from 32 weeks or ZDV from 36 weeks and sdNVP in labour). Prematurity (<37 weeks), low birth weight (<2500 g), stillbirth and neonatal mortality (<28 days) rates were compared.

RESULTS: Of 204 pregnant women enrolled between August 2003-December 2004, 91 began HAART at 30 weeks of gestation in median (range: 17-40) and 114 constituted the PMTCT group. The median CD4 count in the HAART group was 185/mm³ (range: 16-362). We found no significant statistical difference regarding the crude rate of prematurity (3.4% in HAART group vs. 2.0%; p=0.67). The median birth weight was 2800g in the HAART group vs 3000g in the PMTCT group (p=0.01) and the proportion of low birth weight 23.5% and 12.0% respectively (p=0.04). Stillbirth rate was 4.6% in the HAART group and 4.0% in the PMTCT group (p=0.85). Neonatal mortality rate in women treated by HAART was 3.4% vs. 2.0% in the PMTCT group (p=0.67).

CONCLUSIONS: We found a higher rate of low birth weight in HAART treated women compared to women not eligible for HAART treatment, but no difference in stillbirth and neonatal mortality rates. Further larger scale investigations should be performed to assess the risk of HAART on pregnant women in the context of scaling up in low-income countries.

Download PDF of this abstract.

050724
TuFo0202
PMTCT, toxicity and resistance

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.